BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2308 related articles for article (PubMed ID: 2832438)

  • 21. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium.
    Swahn ML; Bygdeman M; Cekan S; Xing S; Masironi B; Johannisson E
    Hum Reprod; 1990 May; 5(4):402-8. PubMed ID: 2113927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypothalamic gonadotropin-releasing hormone secretion and follicle-stimulating hormone dynamics during the luteal-follicular transition.
    Hall JE; Schoenfeld DA; Martin KA; Crowley WF
    J Clin Endocrinol Metab; 1992 Mar; 74(3):600-7. PubMed ID: 1740493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI; Winter JS; Faiman C
    Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
    Cameron ST; Thong KJ; Baird DT
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mechanism of LH release with synthetic LH-RH (author's transl)].
    Koyama T
    Nihon Naibunpi Gakkai Zasshi; 1976 Sep; 52(9):881-97. PubMed ID: 828583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in the ovarian dynamics and endocrine profiles in goats treated with a progesterone antagonist during the early luteal phase of the estrous cycle.
    Suganuma C; Kuroiwa T; Tanaka T; Kamomae H
    Anim Reprod Sci; 2007 Oct; 101(3-4):285-94. PubMed ID: 17027203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM; Nestor JJ; Vickery BH
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of anti-progesterones as a medical IUD.
    Nieman LK; Loriaux DL
    Baillieres Clin Obstet Gynaecol; 1988 Sep; 2(3):609-16. PubMed ID: 3233821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
    Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
    Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
    Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
    J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luteal responses to gonadotropin-releasing hormone during the luteal phase: relation to the age of corpus luteum.
    Caruso A; Lanzone A; Fulghesu AM; Mancuso S
    J Clin Endocrinol Metab; 1987 Feb; 64(2):274-8. PubMed ID: 3098770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle.
    Nippoldt TB; Reame NE; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1989 Jul; 69(1):67-76. PubMed ID: 2499593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypothalamus-pituitary-ovarian axis in cyclic rats lacking progesterone actions.
    Sánchez-Criado JE; Galiot F; Bellido C; Gonzalez D; Tébar M
    Biol Reprod; 1993 Apr; 48(4):916-25. PubMed ID: 8485257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follicular fluid treatment during the follicular versus luteal phase of the menstrual cycle: effects on corpus luteum function.
    Stouffer RL; Hodgen GD; Ottobre AC; Christian CD
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1027-33. PubMed ID: 6427256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the antiprogesterone RU486 in the early follicular phase of the menstrual cycle.
    Stuenkel CA; Garzo VG; Morris S; Liu JH; Yen SS
    Fertil Steril; 1990 Apr; 53(4):642-6. PubMed ID: 2156736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic changes in circulating inhibin levels during the luteal-follicular transition of the human menstrual cycle.
    Roseff SJ; Bangah ML; Kettel LM; Vale W; Rivier J; Burger HG; Yen SS
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1033-9. PubMed ID: 2507568
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 116.